top of page

Rapport Therapeutics has derived what it believes is 'unprecedented' early efficacy for its precision neuroscience treatment in focal onset seizures - its confidence comes from a unique trial design

  • Dec 10, 2025
  • 1 min read

CEO Abe Ceesay describes Rapport's precision neuroscience approach of targeting the AMPA receptor specifically through TARPγ8, and explains why the company took the extra step of tracking an electrographic biomarker in its phase 2a study in addition to seizure frequency. Plus, next steps and additional indications.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page